AbCellera Biologics Inc. (ABCL) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -194.9%, revenue growth -76.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $75.13M |
| Revenue (TTM) | $0.1B |
| Net Margin | -194.9% |
| Operating Margin (TTM) | -340.2% |
| Revenue Growth (YoY) | -76.3% |
| EPS Growth (YoY) | 50.0% |
| FCF Growth (YoY) | -70.4% |
| Price / Book | 3.87 |
| Price / Sales | 52.42 |
| FCF Yield | -5.0% |
| Altman Z-Score | 5.35 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
ABCL overview · ABCL earnings · ABCL KPIs · ABCL documents · ABCL ownership · ABCL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.